The Selective Serotonin 5-HT2A Receptor Agonist (S)-3-(2,5-Dimethoxy-4-(trifluoromethyl)phenyl)piperidine (LPH-5) Induces Persistent and Robust Antidepressant-Like Effects in Rodents
ACS Pharmacology & Translational Science – May 29, 2025
Source: OpenAlex
Summary
A novel **piperidine** compound, LPH-5, demonstrates potent **antidepressant**-like effects in rats, a breakthrough for **Drug Studies**. Its unique **chemistry**, with a **trifluoromethyl** group, allows precise **chemical synthesis**. This **pharmacology** reveals LPH-5 acts as a selective partial **agonist** at the **serotonin 5-HT2A receptor**, showing pronounced selectivity over other **5-HT receptor** subtypes. This specific **receptor** activation profoundly influences **neurotransmitter receptor influence on behavior**, inducing robust, persistent mood improvements. This work, inspired by **alkaloids** like classical **psychedelics**, highlights new treatment potential.
Abstract
Psychedelics have emerged as a promising treatment for mental health disease, and the therapeutic potential of psilocybin and lysergic acid diethylamide (LSD) is presently being pursued in numerous clinical trials. This has prompted a search for novel agents with more specific pharmacological activities than the rather promiscuous classical psychedelics. Here we present the detailed pharmacological characterization of one such compound, LPH-5 [(S)-3-(2,5-dimethoxy-4-(trifluoromethyl)-phenyl)-piperidine]. LPH-5 was found to be a potent partial agonist at the 5-HT2A receptor (5-HT2AR) with pronounced selectivity for 5-HT2AR over the related 5-HT2BR and 5-HT2CR in a range of functional assays. LPH-5 dose-dependently induced head-twitch responses (HTR) as well as robust acute and persistent antidepressant-like effects in rats. These results suggest that selective 5-HT2AR activation holds antidepressant potential and indicate that this activity component is key for the therapeutics effects of classical psychedelics.